TOLREMO receives additional CHF 4.7M in Series A financing

09.06.2020 16:17, Gianmaria Sbetta

Swiss biotech company TOLREMO therapeutics AG developing resistance-preventing precision therapies for patients with cancer, announced today the second closing of its Series A round totalling CHF 13.7 million.

Tolremo has developed a unique cancer drug resistance platform which enables the creation of add-on therapies to existing cancer therapies. Today, despite medical advances, resistance to cancer therapies continues to limit the long-term survival of many patients. This innovative therapeutic approach eradicates the cancer cells that cause drug resistance and meaningfully extends the lives of patients suffering from cancer.

The biotech company, incorporated in March 2017, ranked in the TOP 100 Swiss Startup Award in 2018 and 2019 and was selected as Venture Leader Life Science. 

"Venture Leaders was a fantastic program that allowed me to expand my professional network to the Boston-based venture capital ecosystem. It was very encouraging to see that our value proposition was received very favourably by US investors." Dr. Stefanie Flückiger-Mangual, CEO and co-founder of TOLREMO.



The company raised a CHF 9 million Series A financing round in September 2018 and announced today the second closing of its Series A round totalling CHF 13.7 million. The second closing was led by Swiss venture capital firms BioMedPartners AG and Altos Venture AG. Existing participating investors included the Swiss venture capital firm Redalpine Venture Partners AG as well as the Swiss bank Zürcher Kantonalbank and several experienced private biotech investors.

The additional funds are dedicated to the development of TOLREMO’s first clinical candidate and to the further strengthening of the company’s preclinical pipeline of resistance-preventing assets.

“We are delighted about the strong commitment and continuous financial support from our strong shareholder base. Drug resistance in cancer continues to be a major hurdle in achieving long-term patient benefit. The additional funds bring us one step closer to delivering a new wave of resistance-preventing precision therapies to patients with cancer,” commented Dr. Stefanie Flückiger-Mangual, CEO and co-founder of TOLREMO.